![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
In patients with multiple sclerosis (MS) fatigue is the most common symptom and one of the most disabling features. A s many as 40% have described it as the single most disabling symptom - a higher percentage than weakness, spasticity, motor problems, or bowel or bladder problems. The etiology and patho physiology of MS-related fatigue remain unknown. Studies have failed to demonstrate an association between MS-related fatigue and the level of disability, clinical disease subtype, or gender, although recent data show an association between MS-related fatigue and depression and quality of life. Imaging studies using positron emission tomography suggest that fatigue in MS is related to hypometabolism of specific brain areas, including the frontal and subcortical circuits. The impact of fatigue on patient functioning and quality of life clearly warrants intervention. In addition to nonpharmacologic measures, such as exercise and energy conservation strategies, several pharmacologic agents have been evaluated for their ability to reduce MS-related fatigue, including amantadine, central nervous system stimulants (pemoline), and the novel wake-promoting agent modafinil.
|
Weinshenker BG , Penman M , Bass B , Ebers et al. A double-blind, randomized crossover trial of pemoline in fatigue associated with multiple sclerosis . Neurology 1992; 42: 1468-1471 . Google Scholar | Crossref | Medline | ISI | |
|
The Canadian MS Research Group . A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis . Can J Neurol Sci 1987; 14: 273-278 . Google Scholar | Crossref | Medline | ISI | |
|
Petajan JH , Gappmeier E , White AT , Spencer MK et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis . Ann Neurol 1996; 39: 432-441 . Google Scholar | Crossref | Medline | ISI | |
|
Bakshi R , Shaikh ZA , Miletich RS , Czarnecki D et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability . Mult Scler 2000; 6: 181-185 . Google Scholar | SAGE Journals | ISI | |
|
Freal JE , Kraft GH , Coryell JK. Symptomatic fatigue in multiple sclerosis . Arch Phys Med Rehabil 1984; 65: 135-138 . Google Scholar | Medline | ISI | |
|
Murray TJ. Amantadine therapy for fatigue in multiple sclerosis . Can J Neurol Sci 1985; 12: 251-254 . Google Scholar | Crossref | Medline | ISI | |
|
Krupp LB , Alvarez LA , LaRocca NG , Scheinberg LC. Fatigue in multiple sclerosis . Arch Neurol 1988; 45: 435-437 . Google Scholar | Crossref | Medline | |
|
Bergamaschi R , Romani A , Versino M , Poli R et al. Clinical aspects of fatigue in multiple sclerosis . Funct Neurol 1997; 12: 247-251 . Google Scholar | Medline | ISI | |
|
Fisk JD , Pontefract A , Ritvo PG , Archibald CJ et al. The impact of fatigue on patients with multiple sclerosis . Can J Neurol Sci 1994; 21: 9-14 . Google Scholar | Crossref | Medline | ISI | |
|
Schwartz CE , Coultard-Morris L , Zeng Q. Psychosocial correlates of fatigue in multiple sclerosis . Arch Phys Med Rehabil 1996; 77: 165-170 . Google Scholar | Crossref | Medline | ISI | |
|
Ritvo PG , Fisk JD , Archibald CJ , Murray TJ et al. Psychosocial and neurologic predictors of mental health in multiple sclerosis patients . J Clin Epidemiol 1996; 49: 467-472 . Google Scholar | Crossref | Medline | ISI | |
|
Ng AV , Kent-Braun JA. Quantification of lower physical activity in persons with multiple sclerosis . Med Sci Sports Exerc 1997; 29: 517-523 . Google Scholar | Crossref | Medline | ISI | |
|
Kent-Braun JA , Sharma KR , Weiner MW , Miller RG. Effects of exercise on muscle activation and metabolism in multiple sclerosis . Muscle Nerve 1994; 17: 1162-1169 . Google Scholar | Crossref | Medline | ISI | |
|
Krupp LB , Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders . Curr Opin Neurol 1996; 9: 456-460 . Google Scholar | Crossref | Medline | ISI | |
|
Janardhan V , Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression . J Neurol Sci 2002; 205: 51-58 . Google Scholar | Crossref | Medline | ISI | |
|
Krupp LB , LaRocca NG , Muir-Nash J , Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus . Arch Neurol 1989; 46: 1121-1123 . Google Scholar | Crossref | Medline | |
|
Multiple Sclerosis Clinical Practice Guideline . Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC: Paralyzed Veterans Association , 1999. Available at http://www.pva.org/NEWPVASITE/publications/pubs/mscpg.htm (accessed 25 March 2003). Google Scholar | |
|
Iriarte J , Katsamakis G , deCastro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis . Mult Scler 1999; 5: 10-16 . Google Scholar | SAGE Journals | ISI | |
|
Krupp LB , Coyle PK , Dascher C , Miller A et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo . Neurology 1995; 45: 1956-1961 . Google Scholar | Crossref | Medline | ISI | |
|
Schwid SR , Thorton CA , Pandya S , Manzur KL et al. Quantitative assessment of motor fatigue and strength in MS . Neurology 1999; 53: 743-750 . Google Scholar | Crossref | Medline | ISI | |
|
Krupp LB , Elkins LE. Fatigue and declines in cognitive functioning in multiple sclerosis . Neurology 2000; 55: 934-939 . Google Scholar | Crossref | Medline | ISI | |
|
Cohen RA , Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis . Arch Neurol 1989; 46: 676-680 . Google Scholar | Crossref | Medline | |
|
Bakshi R , Miletich RS , Kinkel PR , Emmet ML et al. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis . J Neuroimaging 1998; 8: 228-234 . Google Scholar | Crossref | Medline | ISI | |
|
Roelcke U , Kappes L , Lechner-Scott J , Brunnschweiler H et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study . Neurology 1997; 48: 1566-1571 . Google Scholar | Crossref | Medline | ISI | |
|
Bakshi R , Ariyaratana S , Benedict RHB , Jacobs L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions . Arch Neurol 2001; 58: 742-748 . Google Scholar | Crossref | Medline | |
|
Bakshi R , Benedict RH , Bermel RA , Caruthers SD et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study . Arch Neurol 2002; 59: 62-68 . Google Scholar | Crossref | Medline | |
|
Bermel RA , Innus MD , Tjoa CW , Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study . NeuroReport 2003; 14: 335-339 . Google Scholar | Crossref | Medline | ISI | |
|
Bakshi R , Miletich RS , Hanschel K , Shaikh ZA et al. Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients . Neurology 1999; 53: 1151-1153 . Google Scholar | Crossref | Medline | ISI | |
|
Mainero C , Faroni J , Gasperini C , Filippi M et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis . J Neurol 1999; 246: 454-458 . Google Scholar | Crossref | Medline | ISI | |
|
Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis . N Engl J Med 1982; 306: 1529-1533 . Google Scholar | Crossref | Medline | ISI | |
|
Wucherpfennig KW , Hafler DA. A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide . Ann NY Acad Sci 1995; 756: 241-258 . Google Scholar | Crossref | Medline | ISI | |
|
Sheean GL , Murray NM , Rothwell JC , Miller DH et al. An electrophysiological study of the mechanism of fatigue in multiple sclerosis . Brain 1997; 120(Suppl 2): 299-315 . Google Scholar | Crossref | Medline | ISI | |
|
Paty DW , Noseworthy JH , Ebers GC. Diagnosis of multiple sclerosis. In Paty DW , Ebers GC eds. Multiple sclerosis. Philadelphia, PA: FA Davis , 1998: 48-134. Google Scholar | |
|
Chaudhuri A , Behan PO. Fatigue and basal ganglia . J Neurol Sci 2000; 179(Suppl 1, pt2): 34-42 . Google Scholar | Crossref | Medline | ISI | |
|
Friedman J , Friedman H. Fatigue in Parkinson’s disease . Neurology 1993; 43: 2016-2018 . Google Scholar | Crossref | Medline | ISI | |
|
Wessely S , Powell R. Fatigue syndromes: a comparison of chronic ‘postviral’ fatigue with neuromuscular and affective disorders . J Neurol Neurosurg Psychiatry 1989; 52: 940-948 . Google Scholar | Crossref | Medline | ISI | |
|
Djaldetti R , Ziv I , Achiron A , Melamed E. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative analysis . Neurology 1996; 46: 632-635 . Google Scholar | Crossref | Medline | ISI | |
|
Schubert M , Wohlfarth K , Rollnik JD , Dengler R. Walking and fatigue in multiple sclerosis: the role of the corticospinal system . Muscle Nerve 1998; 21: 1068-1070 . Google Scholar | Crossref | Medline | ISI | |
|
Petajan JH , White AT. Recommendations for physical activity in patients with multiple sclerosis . Sports Med 1999; 27: 179-191 . Google Scholar | Crossref | Medline | ISI | |
| Cylert® [package insert]. East Chicago, IL: Abbott Laboratories, 1999. Google Scholar | |
|
Rammohan KW , Rosenberg JH , Lynn DJ , Blumenfeld AM et al. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two-centre phase 2 study . J Neurol Neurosurg Psychiatry 2002; 72: 179-183 . Google Scholar | Crossref | Medline | ISI | |
|
Lin JS , Hou Y , Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat . Proc Natl Acad Sci USA 1996; 93: 14128-14133 . Google Scholar | Crossref | Medline | ISI | |
|
Scammell TE , Estabrooke IV , McCarty MT , Chemelli RM et al. Hypothalamic arousal regions are activated during modafinilinduced wakefulness . J Neurosci 2000; 20: 8620-8628 . Google Scholar | Crossref | Medline | ISI | |
|
US Modafinil in Narcolepsy Multicenter Study Group . Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy . Neurology 2000; 54: 1166-1175 . Google Scholar | Crossref | Medline | ISI | |
|
Pigeau R , Naitoh P , Buguet A , McCann C et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work, I: effects on mood, fatigue, cognitive performance and body temperature . J Sleep Res 1995; 4: 212-228 . Google Scholar | Crossref | Medline | ISI | |
|
Arnulf I , Homeyer P , Garma L , Whitelaw WA et al. Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients . Respiration 1997; 64: 159-161 . Google Scholar | Crossref | Medline | ISI | |
|
Menza MA , Kaufman KR , Castellanos A. Modafinil augmentation of antidepressant treatment in depression . J Clin Psychiatry 2000; 61: 378-381 . Google Scholar | Crossref | Medline | ISI |
